KYNTRA BIO, INC.
KYNBNext catalyst
FOR46
Metastatic Castration-resistant Prostate Cancer
Get an email about KYNB's next catalysts
Track KYNTRA BIO (KYNB) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (earnings).See the timeline
2 upcoming, 0 past
KYNB Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-3.66 | FQ end Sep/2026 | Call: tbd
FOR46 Phase 2 Est. Readout
Estimated primary completion for FOR46 trial (NCT05011188) in Metastatic Castration-resistant Prostate Cancer. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
Kyntra Bio, Inc. (formerly FibroGen, Inc.) is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate.
WebsiteFG-4592
Anemia
Epoetin Alfa
Anemia in End Stage Renal Disease
SEPO®
Chemotherapy Induced Anemia
Roxadustat
Anemia Associated With End Stage Renal Disease (ESRD)
Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX
Pancreatic Cancer Non-resectable
Iron
Anemia
Pamrevlumab
Idiopathic Pulmonary Fibrosis
FOR46
Metastatic Castration-resistant Prostate Cancer
FG-3019
Idiopathic Pulmonary Fibrosis
FG2216
Renal Anemia
Oral Iron
Dialysis
FG-3246
Metastatic Castration-Resistant Prostate Cancer
IV Iron
Dialysis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
FG-4592 | Phase 3 | Anemia | - | - |
Epoetin Alfa | Phase 3 | Anemia in End Stage Renal Disease | - | - |
SEPO® | Phase 3 | Chemotherapy Induced Anemia | - | - |
Roxadustat | Phase 3 | Anemia Associated With End Stage Renal Disease (ESRD) | - | - |
Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX | Phase 3 | Pancreatic Cancer Non-resectable | - | - |
Iron | Phase 3 | Anemia | - | - |
Pamrevlumab | Phase 2 | Idiopathic Pulmonary Fibrosis | - | - |
FOR46 | Phase 2 | Metastatic Castration-resistant Prostate Cancer | - | - |
FG-3019 | Phase 2 | Idiopathic Pulmonary Fibrosis | - | - |
FG2216 | Phase 2 | Renal Anemia | - | - |
Oral Iron | Phase 2 | Dialysis | - | - |
FG-3246 | Phase 2 | Metastatic Castration-Resistant Prostate Cancer | - | - |
IV Iron | Phase 2 | Dialysis | - | - |
Frequently asked questions
What is in KYNTRA BIO, INC.'s drug pipeline?→
CatalystAlert tracks 13 drug candidates in KYNTRA BIO, INC.'s (KYNB) pipeline across Phase 3, Phase 2. Its lead program is Epoetin Alfa (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is KYNTRA BIO, INC.'s next FDA catalyst?→
KYNTRA BIO, INC.'s (KYNB) next tracked catalyst is a Phase 2 readout expected Q3 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track KYNB biotech catalysts?→
Add KYNB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow KYNTRA BIO, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.